Interstitial Lung Disease
Journal Scan

Antifibrotics effective for idiopathic pulmonary fibrosis

Posted on

Patients with idiopathic pulmonary fibrosis treated with antifibrotics had significantly greater PFS than patients not treated, according to a study.

In this single-center retrospective observational study at a specialized interstitial lung disease center, progression-free survival (PFS), mortality and drug tolerability were compared between 104 patients with IPF on antifibrotic therapies and 64 patients in an untreated control group.

At 6 months, PFS was significantly greater in the antifibrotic group (75.0%) compared with the control group (56.3%); PFS was not significant at 12 or 18 months between groups.

Independent predictors of 12-month mortality included:

Baseline Body Mass Index of≤25
Baseline diffusion capacity for carbon monoxide percentage predicted of ≤35
Antifibrotic discontinuation within 3 months
By 3 months and 6 months, discontinuation was significantly higher for patients on pirfenidone than those on nintedanib; there was no significant difference at 12 months.

Wright WA, Crowley LE, Parekh D, et al. Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis. BMJ Open Respir Res. 2021;8(1):e000782. doi: 10.1136/bmjresp-2020-000782. PMID: 33771813.